MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
What's Going On With Merck Stock Friday? - Merck & Co ( NYSE:MRK ) , Cidara Therapeutics ( NASDAQ:CDTX )
Merck & Co. Inc. ( NYSE:MRK ) on Friday agreed to acquire Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
WARMINSTER, Pa., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a corporate update.
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock.
Telemark Asset Management, LLC established a new position in Moderna ( NASDAQ:MRNA ) , acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November 10, 2025, SEC filing.According to a filing with the U.S.
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast - Moderna ( NASDAQ:MRNA )
Moderna Inc. ( NASDAQ:MRNA ) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago. The COVID-19 vaccine maker reported quarterly sales of $1.02 billion, topping the expected $886.54 million.
Moderna Q3 2025 Earnings Call Transcript - Moderna ( NASDAQ:MRNA )
Moderna, Inc ( NASDAQ:MRNA ) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below. MRNA is building positive momentum. Watch the momentum here
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment ...
Earnings Data Deluge
Pre-market indexes are bounding into positive territory at this hour, after wallowing in the red following yesterday's solid gains. One might say the relative volatility we started seeing in early October - back when the government shutdown first happened - has continued into this month as well.
Pre-Markets Improve on Big Earnings Morning
One might say the relative volatility we started seeing in early October has continued into this month as well.
Moderna ( MRNA ) Reports Q3 Loss, Tops Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of +76.28% and +18.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer ( SITC ) Annual Meeting
- CX-801 ( PROBODY® interferon alpha-2b ) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma ...
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer ( SITC ) Annual Meeting - CytomX Therapeutics ( NASDAQ:CTMX )
- CX-801 ( PROBODY® interferon alpha-2b ) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801's mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA® ( pembrolizumab ) -
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Moderna Stock Is Sliding Monday: What's Going On? - Moderna ( NASDAQ:MRNA )
Moderna Inc ( NASDAQ:MRNA ) stock is trading sharply lower on Monday afternoon as recent clinical setbacks overshadowed positive pipeline news. MRNA stock is struggling to find support. Check out the latest moves here.
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More - Palantir Technologies ( NASDAQ:PLTR )
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. Here's a look at the names most likely to be on individual investors' radars. CIFR stock is soaring. Watch the real-time price action here.
Moderna ( MRNA ) Stock Is Trading Lower Friday: What's Going On? - Moderna ( NASDAQ:MRNA )
Moderna Inc ( NASDAQ:MRNA ) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here's what investors need to know.
Moderna, Inc. ( MRNA ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
Strength Seen in Moderna ( MRNA ) : Can Its 13.9% Jump Turn into More Strength?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Moderna Inc Gaining or Losing Market Support? - Moderna ( NASDAQ:MRNA )
Moderna Inc's ( NYSE:MRNA ) short interest as a percent of float has fallen 12.38% since its last report. According to exchange reported data, there are now 65.04 million shares sold short, which is 20.25% of all regular shares that are available for trading.
Earnings Preview: Moderna ( MRNA ) Q3 Earnings Expected to Decline
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of ...
Moderna ( MRNA ) Outperforms Broader Market: What You Need to Know
Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Lancaster Opens $7 Million Position in 10x Genomics ( TXG )
On October 8, 2025, Lancaster Investment Management disclosed a new position in 10x Genomics ( NASDAQ:TXG ) . It opened its position in the single cell research company with the acquisition of around $7.27 million in shares.According to a filing with the Securities and Exchange Commission dated ...
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection Moderna Ends Trial As Vaccine Falls Short In Preventing Infection - Moderna ( NASDAQ:MRNA )
Moderna, Inc. ( NASDAQ:MRNA ) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company's investigational cytomegalovirus ( CMV ) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.
Moderna ( MRNA ) Dips More Than Broader Market: What You Should Know
Moderna (MRNA) closed at $26.85 in the latest trading session, marking a -2.33% move from the prior day.
Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.
The biotech's innovative qualities will come in handy.
Should You Buy Moderna Right Now?
Shares could keep sliding, as Moderna's post-COVID pipeline has yet to reach a breakthrough.
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fall
Don't try to catch a falling surgical knife.
Dow Jumps More Than 500 Points Ahead Of Earnings: Investor Fear Eases, Greed Index Remains In 'Fear' Zone - Cleveland-Cliffs ( NYSE:CLF )
The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the "Fear" zone on Monday.
Stock Market Today: S&P 500, Nasdaq, Dow Jones Futures Rise- Micron, Bitmine, Coinbase In Focus - SPDR S&P 500 ( ARCA:SPY )
U.S. stock futures rose on Monday following Friday's advances. Futures of major benchmark indices were higher. On Sunday, President Donald Trump again warned that the U.S. economy would face significant challenges if the Supreme Court rules against the majority of the tariffs imposed this year.
Why Moderna Might Be a One-Hit Wonder
Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.
Moderna ( MRNA ) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Novavax ( NASDAQ:NVAX )
Shah Capital is reportedly pressing Novavax Inc. ( NASDAQ:NVAX ) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. The hedge fund holds a 7.2% stake and is the company's second-largest shareholder.
David Gardner: 9 Foolish Truths I Hold to Be Self-Evident
Whether you're well steeped in Foolishness or at the beginning stages of your investing journey, these are nine foundational truths not to be forgotten.
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients - Moderna ( NASDAQ:MRNA )
Moderna Inc. ( NASDAQ:MRNA ) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkpoint inhibitor-resistant/refractory ( CPI-R/R ) melanoma will be presented at the 2025 ...
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Moderna ( MRNA ) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Moderna (MRNA) stood at $27.92, denoting a +2.12% move from the preceding trading day.
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna ( MRNA ) Beats Stock Market Upswing: What Investors Need to Know
Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
Moderna ( MRNA ) Recently Broke Out Above the 50-Day Moving Average
When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?
Moderna Stock Is Rallying Wednesday: What's Driving The Action? - Moderna ( NASDAQ:MRNA )
Moderna Inc ( NASDAQ:MRNA ) stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector. The rally follows a landmark agreement Tuesday between Pfizer Inc ( NYSE:PFE ) and the Trump administration to lower prescription drug prices.
2 Beaten-Down Stocks to Buy and Hold for a Decade
These biotechs should benefit from their innovative ways.
Moderna ( MRNA ) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, Moderna (MRNA) stood at $24.61, denoting a -4.91% move from the preceding trading day.
Flagship Pioneering, Creator Of Moderna, Launches Extuitive With $20M To Reinvent Consumer Products Using AI Shoppers - Moderna ( NASDAQ:MRNA )
Flagship Pioneering, the Cambridge venture firm known for creating Moderna MRNA, last Thursday unveiled a new startup called Extuitive with $20 million in seed funding.
Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows - Moderna ( NASDAQ:MRNA )
Moderna Inc. MRNA on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ( COVID-19 Vaccine, mRNA ) , which targets the LP.8.1 variant of SARS-CoV-2.
Is Moderna Gaining or Losing Market Support? - Moderna ( NASDAQ:MRNA )
Moderna's MRNA short interest as a percent of float has fallen 4.79% since its last report. According to exchange reported data, there are now 59.84 million shares sold short, which is 21.49% of all regular shares that are available for trading.
